Authors
Zijin Chen, Xiaoyi Zhong, Mengying Yao, Yanying Liu, Jun Chen, Qigang Lan, Yukai Lu, Fang Chen, Mo Chen, Yang Xu, Zihui Xu, Junping Wang, Mengjia Hu, Jinghong Zhao
Published in
Experimental cell research. Pages 115190. Oct 02, 2026. Epub Oct 02, 2026.
Abstract
Chronic kidney disease (CKD) is commonly linked to hematopoietic abnormalities beyond the well-recognized anemia, with underlying mechanisms poorly understood. Here, we show that asymmetric dimethylarginine (ADMA), which accumulates in the CKD microenvironment, perturbs hematopoietic stem cell (HSC) homeostasis. Clinical data analysis reveals that serum ADMA levels rise with CKD progression and inversely correlate with the myeloid-to-lymphoid ratio. Notably, ADMA compromises HSC quiescence and long-term repopulating capacity, as observed in CKD mouse models established by 5/6 nephrectomy. Further investigations demonstrate that ADMA hyperactivates mammalian target of rapamycin (mTOR) signaling, promoting the transition from glycolysis to oxidative phosphorylation and inducing reactive oxygen species (ROS) overproduction in HSCs. Mechanistically, ADMA binds with high affinity to protein phosphatase 2 regulatory subunit Bβ (PPP2R2B), relieving its inhibition of mTOR signaling. Inhibition of mTOR signaling by rapamycin or clearance of ROS by NAC reverses ADMA-induced HSC functional defects. Collectively, our findings identify ADMA as a key mediator of CKD-associated hematopoietic dysfunction via the PPP2R2B-mTOR-mitochondria axis, providing a potential therapeutic target.
PMID:
42826876
Bibliographic data and abstract were imported from PubMed on 03 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 18
- Comments 0